Physician profile
Christopher H Lavergne
NPI 1881695302
$133,909.50
in general payments reported to CMS, 2019-2025
22 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,058 · 2021: $44K · 2022: $13K · 2023: $13K · 2024: $20K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,000.00 |
| Food and Beverage | $2,472.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $59,000.00 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Bardy Diagnostics, INC. | $56,000.00 | 2021-2022 | |
| Pfizer INC. | $10,452.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $4,000.00 | 2019 | |
| Medtronic, INC. | $874.77 | 2021-2025 | Venaseal, Closurefast |
| Boston Scientific Corporation | $638.19 | 2021-2025 | Varithena Administration Pack, Bodyguardian |
| Abbott Laboratories | $577.30 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Tactile Systems Technology INC | $487.32 | 2019-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Amgen INC. | $375.46 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $225.50 | 2022 | |
| Acutus Medical, INC. | $210.16 | 2020 | |
| Biotronik INC. | $155.50 | 2019 | |
| Cook Medical LLC | $153.10 | 2022 | |
| Medtronic Vascular, INC. | $143.31 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $127.34 | 2023 | Opsumit, Uptravi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.40 | 2019 | |
| Edwards Lifesciences Corporation | $105.06 | 2022 | |
| Bard Peripheral Vascular, INC. | $93.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.58 | 2019-2023 | |
| United Imaging Healthcare North America, INC. | $27.06 | 2025 | Umi |
| Sanofi-Aventis U.S. LLC | $26.79 | 2019 | |
| Biocompatibles, INC. | $24.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lavergne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.